MedPath

A Machine-learning Model to Predict Lymph Node Metastasis of Intrahepatic Cholangiocarcinoma

Completed
Conditions
Intrahepatic Cholangiocarcinoma
Machine Learning
Interventions
Procedure: lymph nodes dissection
Registration Number
NCT06290739
Lead Sponsor
West China Hospital
Brief Summary

The object of this study is to develop a model for prediction of lymph node metastasis among intrahepatic cholangiocarcinoma (ICC) patients. Intrahepatic cholangiocarcinoma is the second most common kind of primary liver cancer, accounting for approximately 10%-15%. There is a lack of agreement regarding the necessity of performing lymph node dissection (LND) in patients with ICC. Currently, the percentage of LND is below 50%, and the rate of sufficient LND (≥6) has plummeted to less than 20%. Consequently, a large proportion of patients are unable to acquire LN status, which hinders the following systematic treatment strategies after surgery:. Therefore, our objective is to construct a LN metastasis model utilizing machine learning techniques, including patients' clinical data and pathology information, with the goal of offering a reference for patients who have not undergone LND or have had inadequate LND.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
483
Inclusion Criteria
  • 1.Patients who were confirmed with intrahepatic cholangiocarcinoma 2. curative-intent hepatectomy 3. Without concurrent extrahepatic disease
Exclusion Criteria
  • 1.Patients lacking complete pathology information, 2. Patients who didn't get curative resection 3.Patients with concurrent extrahepatic disease or had missing follow-up data

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Intrahepatic cholangiocarcinoma patients who underwent lymph nodes dissectionlymph nodes dissection-
Primary Outcome Measures
NameTimeMethod
Overall survival2010.01-2019.01

Overall survival (OS) refers to the duration between the commencement of surgery and the patient's demise due to any reason.

Secondary Outcome Measures
NameTimeMethod
Disease free survival2010.01-2019.01

Disease-free survival (DFS) refers to the period of time from the date of surgery until the occurrence of a relapse either within or outside the liver.

Trial Locations

Locations (1)

Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University

🇨🇳

Chengdu, Sichuan, China

© Copyright 2025. All Rights Reserved by MedPath